HIVandHepatitis.com
HIV and AIDS Topics
Top News Articles
 
FDA-approved Treatments 
Experimental Treatments
Women / Children
Metabolic Complications
Opportunistic Infections
 Google Custom Search

Meta-analysis Shows Very Low Risk of Heterosexual Transmission if HIV Positive Partner is on Antiretroviral Therapy with Undetectable Viral Load

By Liz Highleyman

Over the past few years, there has been considerable debate about the risk of HIV transmission if the HIV positive partner is receiving effective antiretroviral treatment and has an undetectable HIV viral load.

In January 2008, the Swiss Federal Commission for HIV/AIDS issued a statement indicating that HIV positive individuals on antiretroviral therapy (ART) who are fully adherent, maintain an undetectable viral HIV RNA level for at least 6 months, and have no concurrent sexually transmitted infections for all intents and purposes cannot transmit HIV via heterosexual vaginal intercourse. Some experts have suggested that treating everyone with HIV, regardless of CD4 cell count, might be an effective prevention strategy.

In an effort to synthesize evidence in this area, Suzanna Attia from the University of Bern in Switzerland and colleagues conducted a systematic review and meta-analysis of studies looking at risk of transmission via sexual contact, and its correlation with viral load and ART treatment status. Findings were published in the April 17, 2009 advance online edition of AIDS; results were previously presented in part at the XVII International AIDS Conference last August in Mexico City

The investigators searched the Medline and Embase medical literature databases and conference abstracts from 1996 through 2009, looking for longitudinal studies of serodiscordant couples reporting rates of HIV transmission according to plasma viral load and/or use of ART. They used random-effects Poisson regression models to obtain summary transmission rates. If a study observed no transmission events, the authors estimated an upper 97.5% confidence limit.

Results

The investigators identified studies of 11 relevant cohorts, representing a total of 5021 heterosexual couples.

A total of 461 HIV transmission events were reported in these studies.

The overall rate of HIV transmission from individuals on ART was 0.46 per 100 person-years, based on 5 events.

The transmission rate from an HIV positive partner on ART with viral load below 400 copies/mL was zero, based on 2 studies, with 1.27 per 100 person-years as the upper limit of the estimated range.

The estimated transmission rate was 0.16 per 100 person-years if the HIV positive person is not on ART, based on 5 studies and 1 event.

There were not sufficient data to calculate transmission rates according to the presence or absence of sexually transmitted infections, condom use, or vaginal versus anal intercourse.

"Studies of heterosexual discordant couples observed no transmission in patients treated with ART and with viral load below 400 copies/mL, but data were compatible with one transmission per 79 person-years," the study authors concluded. "Further studies are needed to better define the risk of HIV transmission from patients on ART."

These findings indicate that while the risk of transmission is very low when an HIV positive person is on effective ART -- and treatment can certainly help lower the transmission rate on a community or population level -- there is no guarantee against transmission in any individual case.

Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland; Department of Social Medicine, University of Bristol, UK.

5/08/09

Reference
S Attia, M Egger, M Müller, and others. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. April 17, 2009 [Epub ahead of print]. (Abstract).


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Protease Inhibitors
Agenerase (amprenavir)
Aptivus
(tipranavir)
Crixivan
(indinavir)
Invirase
(saquinavir hard gel)
Kaletra
(lopinavir/ritonavir)
Lexiva
(fosamprenavir)
Norvir
(ritonavir)
Prezista
(darunavir)
Reyataz
(atazanavir)
Viracept
(nelfinavir)
Nucleoside / Nucleotide Reverse
Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry
(maraviroc)
Dual-Class Fixed
Dosed Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)